Aktis Oncology, Inc.(AKTS)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Aktis Oncology, Inc. (AKTS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. AKTS is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Aktis Oncology, Inc. reports quarterly revenue of $3.4M, net income of $-24.1M, free cash flow of $-21.8M. Top institutional holders of AKTS by reported 13-F value include MPM BioImpact, EcoR1 Capital, Blue Owl Capital, based on the most recent SEC filings. AKTS trades on the Nasdaq exchange and files with the SEC under CIK 2035832. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AKTS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aktis Oncology, Inc. directly from SEC EDGAR.